Stoke Therapeutics (STOK) Q2 FY26 earnings call

Stoke Therapeutics reported strong progress in Q2 FY26, highlighted by the rapid enrollment and zero discontinuations in the Phase III EMPEROR study for zorevunersen, targeting a Q3 2027 readout and early 2028 launch. The company also advanced its STK-002 program for ADOA and maintains a robust financial position to support operations through launch. Management emphasized the long-term safety and efficacy data from OLE studies and ongoing regulatory discussions for zorevunersen.